Literature DB >> 15133112

Induction of Mycobacterium avium growth restriction and inhibition of phagosome-endosome interactions during macrophage activation and apoptosis induction by picolinic acid plus IFNgamma.

Teresa F Pais1, Rui Appelberg1.   

Abstract

Treatment of mouse macrophages with picolinic acid (PA) and gamma-interferon (IFNgamma) led to the restriction of Mycobacterium avium proliferation concomitant with the sequential acquisition of metabolic changes typical of apoptosis, mitochondrial depolarization, annexin V staining and caspase activation, over a period of up to 5 days. However, triggering of cell death by ATP, staurosporine or H(2)O(2) failed to affect mycobacterial viability. In contrast to untreated macrophages where extensive interactions between phagosomes and endosomes were observed, phagosomes from treated macrophages lost the ability to acquire endosomal dextran. N-Acetylcysteine was able to revert both the anti-mycobacterial activity of treated macrophages as well as the block in phagosome-endosome interactions. The treatment, however, induced only a minor increase in the acquisition of lysosomal markers, namely Lamp-1, and did not increase to any great extent the acidification of the phagosomes. These data thus suggest that the anti-mycobacterial activity of PA and IFNgamma depends on the interruption of intracellular vesicular trafficking, namely the blocking of acquisition of endosomal material by the microbe.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15133112     DOI: 10.1099/mic.0.26815-0

Source DB:  PubMed          Journal:  Microbiology        ISSN: 1350-0872            Impact factor:   2.777


  9 in total

1.  Incomplete activation of macrophage apoptosis during intracellular replication of Legionella pneumophila.

Authors:  Alaeddin Abu-Zant; Marina Santic; Maelle Molmeret; Snake Jones; Jürgen Helbig; Yousef Abu Kwaik
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

2.  Activity of picolinic acid in combination with the antiprotozoal drug quinacrine against Mycobacterium avium complex.

Authors:  Toshiaki Shimizu; Haruaki Tomioka
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

Review 3.  Pathogenesis of Mycobacterium avium infection: typical responses to an atypical mycobacterium?

Authors:  Rui Appelberg
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

4.  Mycobacterium avium uses apoptotic macrophages as tools for spreading.

Authors:  Julie Early; Kay Fischer; Luiz E Bermudez
Journal:  Microb Pathog       Date:  2010-12-15       Impact factor: 3.738

5.  Nitric oxide-mediated intracellular growth restriction of pathogenic Rhodococcus equi can be prevented by iron.

Authors:  Kristine von Bargen; Jens Wohlmann; Gregory Alan Taylor; Olaf Utermöhlen; Albert Haas
Journal:  Infect Immun       Date:  2011-03-07       Impact factor: 3.441

6.  M. tuberculosis induces potent activation of IDO-1, but this is not essential for the immunological control of infection.

Authors:  Antje Blumenthal; Gayathri Nagalingam; Jennifer H Huch; Lara Walker; Gilles J Guillemin; George A Smythe; Sabine Ehrt; Warwick J Britton; Bernadette M Saunders
Journal:  PLoS One       Date:  2012-05-23       Impact factor: 3.240

Review 7.  The New Frontier of Host-Directed Therapies for Mycobacterium avium Complex.

Authors:  Nathan P Crilly; Samuel K Ayeh; Petros C Karakousis
Journal:  Front Immunol       Date:  2021-01-22       Impact factor: 7.561

8.  Analysis of Differentially Expressed Proteins in Mycobacterium avium-Infected Macrophages Comparing with Mycobacterium tuberculosis-Infected Macrophages.

Authors:  Dongjun Yang; Xin Fu; Shiyi He; Xueping Ning; Min Ling
Journal:  Biomed Res Int       Date:  2017-05-10       Impact factor: 3.411

Review 9.  Genetic Involvement of Mycobacterium avium Complex in the Regulation and Manipulation of Innate Immune Functions of Host Cells.

Authors:  Min-Kyoung Shin; Sung Jae Shin
Journal:  Int J Mol Sci       Date:  2021-03-16       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.